Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study

R Dobson; M Craner; E Waddingham; A Miller; A Cavey; C Blain; Luca G De; N Evangelou; HL Ford; P Gallagher; K George; RGR Dias; P Harman; J Hobart; T King; R Linighan; N MacDougall; M Marta; S Mitchell; R Nicholas; D Rog; A Scalfari; S Webb; S White; J Wilton; C Young; PM Matthews

doi:10.1177/13524585221123682

Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study

R Dobson
, M Craner
, E Waddingham
, A Miller
, A Cavey
, C Blain
, Luca G De
, N Evangelou
, HL Ford
, P Gallagher
, K George
, RGR Dias
, P Harman
, J Hobart
, T King
, R Linighan
, N MacDougall
, M Marta
, S Mitchell
, R Nicholas

D Rog, A Scalfari, S Webb, S White, J Wilton, C Young, PM Matthews

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1177/13524585221123682
Publication status	Published - Oct 2022

Access to Document

10.1177/13524585221123682

Cite this

Dobson, R., Craner, M., Waddingham, E., Miller, A., Cavey, A., Blain, C., De, L. G., Evangelou, N., Ford, HL., Gallagher, P., George, K., Dias, RGR., Harman, P., Hobart, J., King, T., Linighan, R., MacDougall, N., Marta, M., Mitchell, S., ... Matthews, PM. (2022). Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study. https://doi.org/10.1177/13524585221123682

@conference{7c52ddc751074118aa3ec2e64ab8c25e,

title = "Differences between clinical trials and {"}real-world{"} use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study",

author = "R Dobson and M Craner and E Waddingham and A Miller and A Cavey and C Blain and De, \{Luca G\} and N Evangelou and HL Ford and P Gallagher and K George and RGR Dias and P Harman and J Hobart and T King and R Linighan and N MacDougall and M Marta and S Mitchell and R Nicholas and D Rog and A Scalfari and S Webb and S White and J Wilton and C Young and PM Matthews",

year = "2022",

month = oct,

doi = "10.1177/13524585221123682",

language = "English",

}

Dobson, R, Craner, M, Waddingham, E, Miller, A, Cavey, A, Blain, C, De, LG, Evangelou, N, Ford, HL, Gallagher, P, George, K, Dias, RGR, Harman, P, Hobart, J, King, T, Linighan, R, MacDougall, N, Marta, M, Mitchell, S, Nicholas, R, Rog, D, Scalfari, A, Webb, S, White, S, Wilton, J, Young, C & Matthews, PM 2022, 'Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study'. https://doi.org/10.1177/13524585221123682

TY - CONF

T1 - Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study

AU - Dobson, R

AU - Craner, M

AU - Waddingham, E

AU - Miller, A

AU - Cavey, A

AU - Blain, C

AU - De, Luca G

AU - Evangelou, N

AU - Ford, HL

AU - Gallagher, P

AU - George, K

AU - Dias, RGR

AU - Harman, P

AU - Hobart, J

AU - King, T

AU - Linighan, R

AU - MacDougall, N

AU - Marta, M

AU - Mitchell, S

AU - Nicholas, R

AU - Rog, D

AU - Scalfari, A

AU - Webb, S

AU - White, S

AU - Wilton, J

AU - Young, C

AU - Matthews, PM

PY - 2022/10

Y1 - 2022/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000866540802357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1177/13524585221123682

DO - 10.1177/13524585221123682

M3 - Conference paper (not formally published)

ER -

Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study

Access to Document

Other files and links

Cite this